Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
$0.26
$0.24
$0.13
$0.84
$10.87M2.28470,969 shsN/A
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
$1.04
-1.4%
$1.41
$1.00
$41.50
$37.82M1.15838,641 shs144,188 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$1.04
+1.9%
$1.31
$0.95
$4.44
$18.24M0.9156,390 shs8,349 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
0.00%0.00%0.00%0.00%0.00%
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
-8.70%-19.23%-30.46%-69.51%+104,999,900.00%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-2.86%+6.25%-16.39%-34.19%-69.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
N/AN/AN/AN/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
0.9079 of 5 stars
0.05.00.00.02.40.00.6
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
2.3724 of 5 stars
3.52.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
0.00
N/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
0.00
N/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
3.00
Buy$7.00573.72% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
N/AN/AN/AN/A$1.56 per shareN/A
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
$83K455.70N/AN/A$42.56 per share0.02
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$525.92K34.69N/AN/A$0.48 per share2.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
-$126.32M-$1.90N/AN/AN/AN/A-223.46%-126.91%N/A
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
-$7.66MN/A0.00N/AN/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$5.80M-$0.59N/AN/AN/A-1,473.04%-88.88%-83.59%7/11/2025 (Estimated)

Latest AMTI, BDRX, and LEXX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/14/2025Q2 2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.16-$0.15+$0.01-$0.15$0.14 million$0.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
N/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
N/A
4.99
4.99
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
0.02
2.16
N/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
29.62
29.62

Institutional Ownership

CompanyInstitutional Ownership
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
41.79%
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
17.51%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%

Insider Ownership

CompanyInsider Ownership
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
15.90%
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
0.34%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
26.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Molecular Transport Inc. stock logo
AMTI
Applied Molecular Transport
1341.34 million34.76 millionOptionable
Biodexa Pharmaceuticals Plc stock logo
BDRX
Biodexa Pharmaceuticals
2036.54 million36.42 millionNot Optionable
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
717.56 million12.92 millionNot Optionable

Recent News About These Companies

Lexaria provides GLP-1 update following industry developments
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Lexaria Bioscience begins dosing for GLP-1 study #5
Lexaria's Human GLP-1 Study #5 Begins Dosing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Molecular Transport stock logo

Applied Molecular Transport NASDAQ:AMTI

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.

Biodexa Pharmaceuticals stock logo

Biodexa Pharmaceuticals NASDAQ:BDRX

$1.03 -0.02 (-1.43%)
As of 11:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$1.04 +0.02 (+1.86%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.